In a lab environment, BPC-157 has been studied for its potential in a variety of areas: Support the integrity of the gastrointestinal mucosa Enhance wound healing in skin, tendons, ligaments, and muscles Modulate inflammatory pathways and oxidative stress Interact with the brain-gut axis, a network that connects the nervous system and digestive system As a side note, though no less important, BPC-157 is considered an unapproved new drug and isnt FDA-approved for any human treatment
Or are there pharmaceutical companies trying to capture these peptide products and capitalize the hell out of them
Vukojevic et al., 2018), produced by amputation, and/or anti-coagulants application, or major vessel occlusion, along with the evidence that pentadecapeptide BPC 157 may prevent and/or attenuate or eliminate, thus, counteracting both arterial thrombosis (Kolovrat et al., 2020) and venous thrombosis (Vukojevic et al., 2018
The one honest exception: TB-500 works partly by mass-action, so a higher local concentration in the brief window before it disperses is at least plausible
